Literature DB >> 20306005

Methodological issues in a cluster-randomized trial to prevent dementia by intensive vascular care.

E Richard1, S A Ligthart, E P Moll van Charante, W A van Gool.   

Abstract

OBJECTIVES: Description of methodological issues in a trial designed to evaluate if a multi-component intervention aimed at vascular risk factors can prevent dementia. DESIGN, SETTING AND PARTICIPANTS: Multi-center, open, cluster-randomized controlled clinical trial (preDIVA) including 3535 non-demented subjects aged 70-78, executed in primary practice and coordinated from one academic hospital. General practices are randomized to standard care or intensive vascular care. INTERVENTION: Vascular care consists of 4-monthly visits to a practice nurse who monitors all cardiovascular risk factors. Hypertension, hypercholesterolemia, overweight, lack of physical exercise and diabetes are strictly controlled according to a protocol and treated in a way, tailored to the characteristics of individual participants. MEASUREMENTS: Primary outcomes are incident dementia and disability; secondary outcomes are mortality, vascular events (stroke, myocardial infarction, peripheral vascular disease), cognitive decline and depression.
RESULTS: Between May 2006 and February 2009, 3535 subjects from 115 general practices have been included. The clusters have an average size of 31 (SD 22, range 2-114). 1658 Patients from 52 practices were randomized to the standard care condition and 1877 patients in 63 practices to the vascular care condition. DISCUSSION: When designing a cluster-randomized trial, clustering of patient data within GP practices leads to a loss of power. This should be adjusted for in the power calculation. Since intensive vascular care will probably lead to a reduction in cardiovascular mortality, the competing risks of mortality and dementia should be taken into account.

Entities:  

Mesh:

Year:  2010        PMID: 20306005     DOI: 10.1007/s12603-010-0072-3

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  8 in total

1.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.

Authors:  B A in t' Veld; A Ruitenberg; A Hofman; L J Launer; C M van Duijn; T Stijnen; M M Breteler; B H Stricker
Journal:  N Engl J Med       Date:  2001-11-22       Impact factor: 91.245

2.  CONSORT statement: extension to cluster randomised trials.

Authors:  Marion K Campbell; Diana R Elbourne; Douglas G Altman
Journal:  BMJ       Date:  2004-03-20

3.  Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress.

Authors:  Edo Richard; Esther Van den Heuvel; Eric P Moll van Charante; Lenny Achthoven; Marinus Vermeulen; Patrick J Bindels; Willem A Van Gool
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jul-Sep       Impact factor: 2.703

4.  Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro.

Authors:  A Beiser; R B D'Agostino; S Seshadri; L M Sullivan; P A Wolf
Journal:  Stat Med       Date:  2000 Jun 15-30       Impact factor: 2.373

Review 5.  Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.

Authors:  M M Breteler
Journal:  Neurobiol Aging       Date:  2000 Mar-Apr       Impact factor: 4.673

6.  Cerebral white matter lesions and the risk of dementia.

Authors:  Niels D Prins; Ewoud J van Dijk; Tom den Heijer; Sarah E Vermeer; Peter J Koudstaal; Matthijs Oudkerk; Albert Hofman; Monique M B Breteler
Journal:  Arch Neurol       Date:  2004-10

7.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons.

Authors:  Julie A Schneider; Zoe Arvanitakis; Woojeong Bang; David A Bennett
Journal:  Neurology       Date:  2007-06-13       Impact factor: 9.910

8.  The AMC Linear Disability Score project in a population requiring residential care: psychometric properties.

Authors:  Rebecca Holman; Robert Lindeboom; Marinus Vermeulen; Rob J de Haan
Journal:  Health Qual Life Outcomes       Date:  2004-08-03       Impact factor: 3.186

  8 in total
  1 in total

Review 1.  Pre-dementia Alzheimer's trials: overview.

Authors:  P S Aisen
Journal:  J Nutr Health Aging       Date:  2010-04       Impact factor: 4.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.